Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.7K
Behavior Therapy01:22

Behavior Therapy

1.1K
Behavior therapy incorporates diverse techniques rooted in classical conditioning principles to address maladaptive behaviors and anxiety disorders. These methods aim to reduce avoidance behaviors, foster adaptive coping mechanisms, and alter associations between stimuli and responses, making them effective in a wide range of therapeutic contexts.
Exposure therapy is a cornerstone of behavioral treatment for anxiety disorders. It involves systematic exposure to feared stimuli, either in real...
1.1K
Centrally Acting Muscle Relaxants: Therapeutic Uses01:24

Centrally Acting Muscle Relaxants: Therapeutic Uses

1.7K
Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
1.7K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.7K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Smartphone-derived digital motor measures to monitor progression in idiopathic REM sleep behavior disorder.

NPJ Parkinson's disease·2026
Same author

Rare-Variant Burden across Lysosomal Genes Implicates Sialylation and Ganglioside Metabolism in Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Oligogenic variants in <i>NEK1</i> and <i>ATXN2</i> in amyotrophic lateral sclerosis: report of two cases and review of the literature.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
Same author

Proteomic Analysis of Corpora Amylacea Extracted From Post-mortem Brain of MAiD-end-of-life Sporadic ALS Patients.

Brain and behavior·2026
Same author

The GBA1 p.E427K (p.E388K) Variant Is a Risk Factor for Synucleinopathies: A Meta-Analysis.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Large-scale exome analyses reveal new rare variant contributions in amyotrophic lateral sclerosis.

Nature genetics·2026

Related Experiment Video

Updated: Apr 29, 2026

Author Spotlight: Deciphering the Role of ATM in Ataxia-Telangiectasia and the Associated Cerebellar Degeneration
08:41

Author Spotlight: Deciphering the Role of ATM in Ataxia-Telangiectasia and the Associated Cerebellar Degeneration

Published on: December 27, 2024

1.5K

Therapies for ataxias.

Laurence Martineau1, Anne Noreau, Nicolas Dupré

  • 1Department of Neurological Sciences of the Centre Hopitalier Universitaire de Québec and Faculty of Medicine, CHU de Québec, Laval University, 1401, 18th Street, Quebec City, Quebec, G1J 1Z4, Canada.

Current Treatment Options in Neurology
|May 17, 2014
PubMed
Summary

Diagnosing the cause of ataxia is crucial for effective treatment. While some ataxias respond to specific therapies, physiotherapy and occupational therapy offer symptomatic relief and improve quality of life for all patients.

More Related Videos

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
07:20

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy

Published on: August 9, 2024

3.0K
A Simple Composite Phenotype Scoring System for Evaluating Mouse Models of Cerebellar Ataxia
07:33

A Simple Composite Phenotype Scoring System for Evaluating Mouse Models of Cerebellar Ataxia

Published on: May 21, 2010

35.4K

Related Experiment Videos

Last Updated: Apr 29, 2026

Author Spotlight: Deciphering the Role of ATM in Ataxia-Telangiectasia and the Associated Cerebellar Degeneration
08:41

Author Spotlight: Deciphering the Role of ATM in Ataxia-Telangiectasia and the Associated Cerebellar Degeneration

Published on: December 27, 2024

1.5K
Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
07:20

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy

Published on: August 9, 2024

3.0K
A Simple Composite Phenotype Scoring System for Evaluating Mouse Models of Cerebellar Ataxia
07:33

A Simple Composite Phenotype Scoring System for Evaluating Mouse Models of Cerebellar Ataxia

Published on: May 21, 2010

35.4K

Area of Science:

  • Neurology
  • Genetics
  • Rehabilitation Medicine

Background:

  • Ataxia presents with diverse etiologies, encompassing both genetic defects and nongenetic factors.
  • Accurate diagnosis is the primary determinant for initiating appropriate therapeutic interventions.
  • Understanding the specific cause of ataxia is essential for identifying potential targeted treatments.

Purpose of the Study:

  • To underscore the importance of accurate diagnosis in managing ataxia.
  • To highlight the range of treatment options available for different ataxia types.
  • To emphasize the role of symptomatic management and rehabilitation in improving patient outcomes.

Main Methods:

  • Review of current literature on ataxia causes and treatments.
  • Analysis of diagnostic approaches for differentiating ataxia etiologies.
  • Evaluation of therapeutic strategies, including specific treatments and supportive care.

Main Results:

  • Nongenetic ataxias, such as those due to vitamin deficiencies, may show improvement with targeted treatment.
  • In many instances, available therapies for ataxia are primarily symptomatic, aiming to manage symptoms rather than cure the underlying cause.
  • Physiotherapy and occupational therapy are universally beneficial, significantly enhancing the quality of life for individuals with all forms of ataxia.

Conclusions:

  • Accurate diagnosis is paramount for effective ataxia management.
  • While specific treatments exist for certain causes, symptomatic therapies and rehabilitation are vital for all patients.
  • Physiotherapy and occupational therapy represent cornerstone treatments for maximizing functional independence and quality of life in ataxia.